CC 90005

Drug Profile

CC 90005

Alternative Names: CC-90005

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Class Antipsoriatics
  • Mechanism of Action Protein kinase C theta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis
  • Preclinical Arthritis

Most Recent Events

  • 28 Sep 2016 Preclinical trials in Arthritis in USA (unspecified route) before September 2016
  • 28 Sep 2016 Pharmacodynamics data from a preclinical study in Arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 26 Feb 2016 Celgene Corporation terminates a phase I trial in Plaque psoriasis in USA (PO) (NCT02502188)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top